### Accepted Manuscript

Efficacy and safety of the PCSK9 monoclonal antibody alirocumab versus placebo with heterozygous familial hypercholesterolemia

John J.P. Kastelein, MD, PhD, FESC, G. Kees Hovingh, MD, PhD, Gisle Langslet, MD, Marie T. Baccara-Dinet, MD, Daniel A. Gipe, MD, Umesh Chaudhari, MD, Jian Zhao, MS, Pascal Minini, PhD, Michel Farnier, MD, PhD

PII: S1933-2874(16)30451-2

DOI: 10.1016/j.jacl.2016.12.004

Reference: JACL 1030

To appear in: Journal of Clinical Lipidology

Received Date: 28 November 2016

Accepted Date: 11 December 2016

Please cite this article as: Kastelein JJP, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M, Efficacy and safety of the PCSK9 monoclonal antibody alirocumab versus placebo with heterozygous familial hypercholesterolemia, *Journal of Clinical Lipidology* (2017), doi: 10.1016/j.jacl.2016.12.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



#### ACCEPTED MANUSCRIPT

# Efficacy and safety of the PCSK9 monoclonal antibody alirocumab versus placebo in 1257 patients with heterozygous familial hypercholesterolemia. Analyses up

#### to 78 weeks from four ODYSSEY trials

John J. P. Kastelein, MD, PhD, FESC, G. Kees Hovingh, MD, PhD, Gisle Langslet, MD, Marie T. Baccara-Dinet, MD, Daniel A. Gipe, MD, Umesh Chaudhari, MD, Jian Zhao, MS, Pascal Minini, PhD, Michel Farnier, MD, PhD

Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands (Drs Kastelein and Hovingh); Lipid Clinic, Oslo University Hospital, Oslo, Norway (Dr Langslet); Sanofi, Montpellier, France (Dr Baccara-Dinet); Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA (Dr Gipe); Sanofi, Bridgewater, NJ, USA (Dr Chaudhari); Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA (Mr Zhao); Sanofi, Chilly-Mazarin, France (Dr Minini); Lipid Clinic, Point Médical, Dijon, France (Dr Farnier)

#### Corresponding author:

Dr John JP Kastelein Department of Vascular Medicine Academic Medical Center Meibergdreef 9 Room F4–159.2 1105 AZ Amsterdam The Netherlands Download English Version:

## https://daneshyari.com/en/article/5615373

Download Persian Version:

https://daneshyari.com/article/5615373

Daneshyari.com